Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has received an average rating of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $19.6667.

ORIC has been the subject of several research analyst reports. Wedbush reissued an “outperform” rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Monday, December 8th. JPMorgan Chase & Co. upped their target price on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Evercore ISI initiated coverage on shares of Oric Pharmaceuticals in a report on Thursday, November 20th. They set an “outperform” rating and a $25.00 price target for the company. Citigroup boosted their price objective on shares of Oric Pharmaceuticals from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Oppenheimer upped their price objective on shares of Oric Pharmaceuticals from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Friday, November 14th.

Insider Activity

In other Oric Pharmaceuticals news, insider Pratik S. Multani sold 10,720 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the transaction, the insider directly owned 68,149 shares of the company’s stock, valued at $617,429.94. This represents a 13.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Dominic Piscitelli sold 11,000 shares of the business’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $14.52, for a total value of $159,720.00. Following the completion of the sale, the chief financial officer directly owned 48,317 shares of the company’s stock, valued at $701,562.84. This represents a 18.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 190,814 shares of company stock worth $2,171,318. 6.82% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC raised its position in shares of Oric Pharmaceuticals by 50.3% in the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock valued at $31,735,000 after purchasing an additional 1,046,154 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Oric Pharmaceuticals by 3,646.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares during the period. Rafferty Asset Management LLC grew its stake in Oric Pharmaceuticals by 50.7% in the 1st quarter. Rafferty Asset Management LLC now owns 77,424 shares of the company’s stock valued at $432,000 after buying an additional 26,032 shares during the last quarter. Alkeon Capital Management LLC grew its stake in Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock valued at $45,717,000 after buying an additional 500,000 shares during the last quarter. Finally, Resolute Capital Asset Partners LLC bought a new position in Oric Pharmaceuticals in the 2nd quarter worth $2,309,000. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Trading Down 2.1%

Oric Pharmaceuticals stock opened at $8.25 on Friday. Oric Pharmaceuticals has a 52 week low of $3.90 and a 52 week high of $14.93. The stock has a market cap of $803.47 million, a price-to-earnings ratio of -4.77 and a beta of 1.32. The company’s 50-day moving average price is $11.20 and its two-hundred day moving average price is $10.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.08. Research analysts expect that Oric Pharmaceuticals will post -2.17 earnings per share for the current fiscal year.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.